Repatha efficacy and safety
Pro Research Analysisby 
Searched over 200M research papers
Repatha (Evolocumab) Efficacy in Lowering LDL Cholesterol
Repatha (evolocumab) is a monoclonal antibody that targets the PCSK9 protein, which plays a key role in regulating LDL cholesterol (LDL-C) levels. By inhibiting PCSK9, Repatha increases the number of LDL receptors on liver cells, allowing more LDL-C to be removed from the bloodstream. Clinical trials have shown that when added to statin therapy, Repatha can reduce LDL-C by 50% to 60% from baseline in patients with high cholesterol, including those with familial hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) 1235+4 MORE. In patients with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD, LDL-C reductions of 54% to 77% have been observed, and about 90% of ASCVD patients achieved LDL-C levels below 70 mg/dL when Repatha was added to maximum statin therapy . For patients with homozygous familial hypercholesterolemia (HoFH), LDL-C reductions of approximately 30% have been reported .
Cardiovascular Outcomes and Additional Lipid Effects
Beyond lowering LDL-C, Repatha has been shown to reduce total cholesterol, non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) 13. The FOURIER trial and its extension (FOURIER-OLE) demonstrated that Repatha significantly reduces the incidence of major cardiovascular events by 15% in patients with ASCVD and residual high cholesterol despite statin therapy . The benefit was consistent even at very low LDL-C levels, supporting the use of Repatha for secondary prevention in high-risk patients 347.
Safety and Tolerability of Repatha
Repatha has demonstrated a favorable safety profile in clinical trials. The most common side effects include nasopharyngitis, upper respiratory tract infection, flu-like symptoms, back pain, and injection-site reactions such as redness, pain, or bruising 1235+2 MORE. Allergic reactions, including rash and hives, have also been reported but are generally rare . Importantly, studies have shown that Repatha does not negatively affect cognitive function, even when LDL-C is reduced to very low levels 37. Overall, Repatha is well tolerated, with no serious adverse reactions commonly observed 137.
Use in Special Populations and Administration
Repatha is indicated for adults with primary hyperlipidemia, including HeFH, HoFH, and ASCVD, who require additional LDL-C lowering beyond what can be achieved with diet and statin therapy 210. It is also an option for patients who are statin-intolerant or cannot reach LDL-C targets with other lipid-lowering agents 16710. The recommended dosing is 140 mg every two weeks or 420 mg once a month, administered via subcutaneous injection 1210.
Conclusion
Repatha (evolocumab) is a highly effective and generally safe option for lowering LDL cholesterol, especially in high-risk patients who do not achieve target LDL-C levels with statins alone. It significantly reduces cardiovascular events and is well tolerated, making it a valuable therapy for managing hypercholesterolemia and preventing atherosclerotic cardiovascular disease 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic